Huntleigh Advisors Inc. Boosts Stake in Exagen Inc. $XGN

Huntleigh Advisors Inc. boosted its stake in shares of Exagen Inc. (NASDAQ:XGN) by 5.7% in the second quarter, Holdings Channel reports. The institutional investor owned 87,861 shares of the company’s stock after acquiring an additional 4,753 shares during the period. Huntleigh Advisors Inc.’s holdings in Exagen were worth $613,000 as of its most recent SEC filing.

Separately, Acadian Asset Management LLC acquired a new position in shares of Exagen during the first quarter worth $25,000. 75.25% of the stock is currently owned by hedge funds and other institutional investors.

Exagen Price Performance

NASDAQ XGN opened at $11.54 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 4.95 and a quick ratio of 4.95. The stock’s fifty day moving average price is $10.19 and its 200 day moving average price is $7.81. Exagen Inc. has a 1 year low of $2.38 and a 1 year high of $11.99. The company has a market cap of $253.88 million, a price-to-earnings ratio of -12.97 and a beta of 1.54.

Exagen (NASDAQ:XGN) last released its earnings results on Tuesday, July 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.18). Exagen had a negative return on equity of 130.38% and a negative net margin of 28.85%.The firm had revenue of $17.20 million for the quarter, compared to the consensus estimate of $16.25 million. Exagen has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Exagen Inc. will post -0.88 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on XGN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exagen in a research report on Wednesday, October 8th. Canaccord Genuity Group upped their price target on Exagen from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, July 30th. B. Riley started coverage on Exagen in a research report on Thursday, September 11th. They set a “buy” rating and a $15.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 price target on shares of Exagen in a research report on Wednesday, July 30th. Finally, KeyCorp upped their price target on Exagen from $12.00 to $15.00 and gave the stock an “overweight” rating in a research report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.60.

Exagen Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).